The estimated Net Worth of Jon K. Hayashida is at least 2.77 百万$ dollars as of 10 May 2021. Jon Hayashida owns over 18,719 units of Staar Surgical Co stock worth over 820,219$ and over the last 5 years he sold STAA stock worth over 1,945,347$. In addition, he makes 0$ as Vice President - Global Clinical and Medical Affairs at Staar Surgical Co.
Sign up
Jon Hayashida STAA stock SEC Form 4 insiders trading
Jon has made over 8 trades of the Staar Surgical Co stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 18,719 units of STAA stock worth 468,349$ on 10 May 2021.
The largest trade he's ever made was selling 47,408 units of Staar Surgical Co stock on 5 December 2019 worth over 1,763,578$. On average, Jon trades about 21,579 units every 58 days since 2019. As of 10 May 2021 he still owns at least 27,061 units of Staar Surgical Co stock.
You can see the complete history of Jon Hayashida stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jon Hayashida biography
Dr. Jon K. Hayashida serves as Vice President - Global Clinical and Medical Affairs of the Company. Dr. Jon K. Hayashida joined STAAR in July 2015 as Vice President of Global Clinical and Medical Affairs. Over the past 30 years, Dr. Hayashida's professional career includes experience in corporate eye care, ophthalmic start-up companies and direct patient care. From 2010 to 2013 he held the position of Vice President of Clinical and Medical Affairs for Bausch and Lomb, Surgical, where he gained FDA approvals for both the Glistening-free enVista Hydrophobic Acrylic IOL and PMA approval for the Trulign Toric Accommodating IOL. He also held Clinical Affairs leadership and research positions with Cooper Vision and Allergan. His Ophthalmic start-up company experience includes Vice President Clinical Affairs for Wavetec Vision, Transcend Medical and Refractec where he directed, planned and executed successful FDA PMA approvals. Dr. Hayashida has served as a clinical care specialist at the UCLA Laser Refractive Center, Jules Stein Institute, UCLA School of Medicine. Most recently, from 2013 to 2015, he served as Vice President of Programs and Services for the Braille Institute of America. He earned his Bachelor of Science and Doctorate of Optometry from Southern California College of Optometry. Dr. Hayashida is a Fellow of the American Academy of Optometry and a Diplomate in its Cornea and Contact Lens and Refractive Technologies Section.
How old is Jon Hayashida?
Jon Hayashida is 62, he's been the Vice President - Global Clinical and Medical Affairs of Staar Surgical Co since 2015. There are 5 older and 16 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.
What's Jon Hayashida's mailing address?
Jon's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Staar Surgical Co
Over the last 21 years, insiders at Staar Surgical Co have traded over 305,974,767$ worth of Staar Surgical Co stock and bought 10,576,326 units worth 122,359,752$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Partners, L.P.Bradsher Neal...、Gilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of 1,643,742$. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth 49,957$.
What does Staar Surgical Co do?
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
What does Staar Surgical Co's logo look like?
Complete history of Jon Hayashida stock trades at Staar Surgical Co
Staar Surgical Co executives and stock owners
Staar Surgical Co executives and other stock owners filed with the SEC include:
-
Caren Mason,
President, Chief Executive Officer, Director -
Scott Barnes,
Chief Medical Officer -
Keith Holliday,
Chief Technology Officer -
Caren L. Mason,
CEO, Pres & Director -
Hans-Martin Blickensdoerfer,
Senior Vice President - Commercial Operations, Direct Markets Europe and China -
Samuel Gesten,
Chief Legal Officer, Corporate Secretary -
Dr. Scott D. Barnes M.D.,
Chief Medical Officer -
James Francese,
Senior Vice President - Commercial Operations, North America and APAC -
Hans-Martin Blickensdoerfer,
Sr. VP of Commercial Operations and Director of Markets - Europe & China -
Dr. Keith Holliday,
Chief Technology Officer -
Patrick F. Williams,
Chief Financial Officer -
Louis Silverman,
Independent Chairman of the Board -
Stephen Farrell,
Independent Director -
John Moore,
Independent Director -
Patrick Williams,
Chief Financial Officer -
Gilbert Kliman,
Director -
Thomas Frinzi,
Director -
Brian Moore,
IR Contact Officer -
Jon Hayashida,
Vice President - Global Clinical and Medical Affairs -
Graydon Hansen,
Chief Manufacturing Officer and Senior Vice President, Global Operations -
Philippe Subrin,
VP of Collamer Lens Manufacturing & GM of Nidau Operations -
Joanne Egamino Ph.D.,
Global Head of Clinical Operations -
James Francese,
Sr. VP of Commercial Operations - North America & APAC -
William Goodmen,
VP of Global HR -
Samuel J. Gesten,
Chief Legal Officer & Corp. Sec. -
Lou Silverman,
Director -
Stephen P Brown,
Vice President & Chief Financi -
Richard A Meier,
Director -
Partners, L.P.Broadwood Cap...,
-
Partners, L.P.Bradsher Neal...,
-
William P Wall,
Director -
David Bailey,
President and CEO -
Robert Studholme,
Senior VP, Operations -
Wei Jiang,
-
Arthur C Butcher,
-
Nathaniel Sisitsky,
General Counsel -
Nicholas T Curtis,
Sr. VP Sales and Marketing -
Paul Hambrick,
Vice President, Operations -
Robert Kenneth Lally,
Vice President, QA/RA -
David L Schlotterbeck,
Director -
James I Farnworth,
VP Reg Affairs & Quality -
Gunther Roepstorff,
President - Domilens GmbH -
John R Gilbert,
Director -
Thomas R Paul,
Vice President - R & D -
John Bily,
Chief Financial Officer -
Volker D Anhaeusser,
Director -
John S Santos,
Sr. VP Planning & Corp Dev -
Jack Steven Roush,
-
Charles P Slacik,
Director -
Robin Hughes,
Vice President, Marketing -
Mark B Logan,
Director -
Barry G Caldwell,
Director -
Don M Bailey,
Director -
Kathryn Tunstall,
Director -
Philippe Subrin,
VP Switzerland OP -
Charles S Kaufman,
V.P. , General Counsel -
Donald J Todd,
President, Asia/Pacific -
Donald L Fagen,
V.P. Sales for N. America -
David R Morrison,
Director -
Craig Felberg,
VP, R&D and Clinical Affairs -
William Walter Goodmen,
Global VP, Human Resources -
Donald Duffy,
Director -
Isamu Kamijo,
President, STAAR Japan Inc. -
K Peony Yu,
Director -
Aimee S Weisner,
-
Magda Michna,
Chief Clinical, Regulatory, -
Warren Foust,
Chief Operating Officer -
Elizabeth Yeu Lin,
-
Lilian Yansheng Zhou,